TEOSYAL® RHA Global Action, TEOSYAL® RHA Deep Lines, and Juvéderm® Ultra XC for the Correction of Nasolabial Folds

Completed · Not applicable

Conditions studied: Nasolabial Folds, Wrinkles

In brief

The purpose of this study is 1) to compare the effectiveness and safety of TEOSYAL® RHA Global Action versus Juvéderm® Ultra XC, and 2) to compare the effectiveness and safety of TEOSYAL® RHA Deep Lines versus Juvéderm® Ultra XC, in the treatment of moderate to severe nasolabial folds.

Key facts

Study ID

NCT02195427

Run by

Teoxane SA

People needed

148

Starts

2014-06-01

Expected to finish

2016-03-01

Last updated by the study team

2018-04-25

Who can join

Age: 22 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Outpatient, male or female of any race, 22 years of age or older; female subjects of childbearing potential must have a negative urine pregnancy test and practice a reliable method of contraception
• NLFs classified as WSRS grade 3 or 4 (same score for each side)
• Willing to abstain from facial aesthetic procedures/therapies that could interfere with study evaluations
• Able to follow study instructions and likely to complete all required visits;
• Signed informed consent and HIPAA (Health Insurance Portability and Accountability Act) form

You may not qualify if…

• Female subjects that are pregnant or breast-feeding, or of childbearing potential and not practicing reliable birth control
• Known hypersensitivity/allergy to any component of the study devices
• Known sensitivity to local anesthetics of the amide type, history of multiple severe allergies, history of anaphylactic shock
• Known susceptibility to keloid formation, hypertrophic scarring or clinically significant skin pigmentation disorders
• Clinically significant active skin disease within 6 months
• History of active chronic debilitating systemic disease
• History of connective tissue disease
• History of malignancy (excl. non-melanoma skin cancer) within past 5 years
• History of bleeding disorders
• Need for clinically significant and continuous medical treatment within 2 weeks prior to first visit
• Received/used a prohibited treatment/procedure within certain time periods (e.g., bioresorbable fillers, NSAIDS, acetylsalicylic acid, high dose vitamin E, corticosteroids, interferon, anti-coagulation therapies, laser/light therapies, botulinum toxin injections (frontalis and glabella complex treatment permitted), prescription strength topical retinoids, facial peels, excisional facial surgery, clinically significant oral or maxillofacial surgery)
• Clinically significant alcohol or drug abuse, or history of poor cooperation, non-compliance with medical treatment, or unreliability
• Exhibit a physical attribute(s) that may prevent assessment or treatment of NLFs such as excessive facial hair, traumatic or surgical facial scars, and/or excessive hyperpigmentation in the treatment areas
• A condition or situation that may put the subject at significant risk, confound the study results, or significantly interfere with the subject participation

Where it is running

• United States, Alabama — Birmingham, Alabama, United States
• United States, California — Beverly Hills, California, United States
• United States, Santa Monica — Santa Monica, California, United States
• United States, Florida — Coral Gables, Florida, United States
• United States, Massachusetts — Chestnut Hill, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.